SAB Biotherapeutics (SABS) Expected to Announce Earnings on Friday

SAB Biotherapeutics (NASDAQ:SABS) is expected to announce its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 9, 2026 at 7:00 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, analysts expect SAB Biotherapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SAB Biotherapeutics Trading Down 1.5%

SABS stock opened at $3.87 on Wednesday. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a twelve month low of $1.00 and a twelve month high of $6.60. The stock has a market capitalization of $197.18 million, a price-to-earnings ratio of -1.67 and a beta of 0.59. The firm’s fifty day simple moving average is $4.03 and its two-hundred day simple moving average is $3.46.

Wall Street Analyst Weigh In

A number of research firms recently commented on SABS. UBS Group began coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $7.00 price target for the company. HC Wainwright reduced their price objective on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, March 10th. Zacks Research downgraded shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Guggenheim assumed coverage on SAB Biotherapeutics in a research note on Friday, December 19th. They set a “buy” rating and a $15.00 target price on the stock. Finally, Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.00.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SABS. Vivo Capital LLC purchased a new position in shares of SAB Biotherapeutics during the third quarter valued at $22,954,000. RA Capital Management L.P. purchased a new stake in SAB Biotherapeutics in the third quarter worth about $8,847,000. Woodline Partners LP purchased a new stake in SAB Biotherapeutics in the third quarter worth about $5,730,000. Perceptive Advisors LLC bought a new position in SAB Biotherapeutics during the 4th quarter worth about $3,004,000. Finally, Balyasny Asset Management L.P. bought a new position in SAB Biotherapeutics during the 4th quarter worth about $1,778,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.